Who are Opalmon's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): prostacyclin, Racemic Cloprostenol, Fundyl, Xalatan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/limaprost.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Opalmon — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Opalmon (LIMAPROST) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: limaprost. Area: Cardiovascular.

marketed limaprost Prostaglandin E2 receptor EP1 subtype Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Opalmon (LIMAPROST).

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Opalmon TARGET	LIMAPROST		marketed	limaprost	Prostaglandin E2 receptor EP1 subtype
prostacyclin	prostacyclin	United Therapeutics	marketed		P2Y purinoceptor 12, Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype
Racemic Cloprostenol	CLOPROSTENOL		marketed		Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP2 subtype, Prostaglandin E2 receptor EP3 subtype
Fundyl	ENPROSTIL		marketed	enprostil	Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype
Xalatan	Xalatan	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed		Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (limaprost class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Opalmon — Competitive Intelligence Brief. https://druglandscape.com/ci/limaprost. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing